BiondVax Pharmaceuticals Ltd. (BVXV) Analysts See $-0.01 EPS

August 13, 2018 - By Mary Kidd

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Logo

Analysts expect BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) to report $-0.01 EPS on August, 30.They anticipate $0.73 EPS change or 98.65 % from last quarter’s $-0.74 EPS. After having $-0.62 EPS previously, BiondVax Pharmaceuticals Ltd.’s analysts see -98.39 % EPS growth. The stock decreased 2.69% or $0.16 during the last trading session, reaching $5.78. About 2,834 shares traded. BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has declined 13.97% since August 13, 2017 and is downtrending. It has underperformed by 26.54% the S&P500.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. The company has market cap of $37.78 million. The Company’s product candidate includes M-001, a synthetic peptide protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. It currently has negative earnings.

Another recent and important BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) news was published by which published an article titled: “Form 6-K BiondVax Pharmaceuticals For: Aug 10” on August 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.